The Department of Veterans Affairs is seeking qualified vendors to produce specialized liposomal formulations incorporating patented joint-targeting technologies for arthritis therapy. Vendors must demonstrate capability in custom liposome or nanoparticle formulation, peptide functionalization, drug encapsulation, and nanoparticle characterization. Performance of services is not specified, but work involves research-grade formulations for non-GLP exploratory studies. No budget amount is provided. Responses are due by July 29, 2026, and a signed Confidential Disclosure Agreement is required before proprietary technical details are shared.